OncoGlory Biotech

OncoGlory Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on developing innovative small molecule therapeutics for oncology. The company specializes in modulating the tumor microenvironment to overcome resistance to immunotherapy and improve patient outcomes in hard-to-treat cancers. Its lead clinical candidate, OG202, is a selective inhibitor of the TGF-β receptor 1 (ALK5) currently being evaluated in Phase 2 trials for solid tumors. OncoGlory's pipeline also includes OG101, a CSF-1R inhibitor, and several undisclosed preclinical programs targeting immune-oncology pathways. The company was founded by industry veterans with experience at major global pharmaceutical firms and is backed by leading venture capital investors.